Cardio Diagnostics (CDIO)
Market Price (3/30/2026): $1.97 | Market Cap: $3.6 MilSector: Health Care | Industry: Biotechnology
Cardio Diagnostics (CDIO)
Market Price (3/30/2026): $1.97Market Cap: $3.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -123% | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -160% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43737% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% | Expensive valuation multiplesP/SPrice/Sales ratio is 242x | |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Show more. | Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -58%, Rev Chg QQuarterly Revenue Change % is -21% | |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 744% | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38630%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -41458% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -185% | ||
| High stock price volatilityVol 12M is 3307% | ||
| Key risksCDIO key risks include [1] an unproven business model with negligible revenue and substantial net losses, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -123% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -46% |
| Megatrend and thematic driversMegatrends include Precision Medicine, Biotechnology & Genomics, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -160% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -6.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -43737% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 242x |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -58%, Rev Chg QQuarterly Revenue Change % is -21% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 744% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -38630%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -41458% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -185% |
| High stock price volatilityVol 12M is 3307% |
| Key risksCDIO key risks include [1] an unproven business model with negligible revenue and substantial net losses, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Cardio Diagnostics (CDIO) stock has lost about 30% since 11/30/2025 because of the following key factors:
1. Significant Q4 2025 Earnings Miss Led to Sharp Decline. Cardio Diagnostics reported a Q4 2025 Earnings Per Share (EPS) of -$0.80 on March 13, 2026, which fell short of analysts' expectations by -55.56%. This earnings disappointment directly impacted the stock, leading to a substantial -47.15% decrease in price within the 48-hour period following the report, dropping from $4.56 on March 12, 2026, to $2.41 on March 14, 2026.
2. Substantial Annual Revenue Contraction. The company experienced a significant decline in its full fiscal year 2025 revenue, which totaled $14,825. This represents a -57.51% decrease compared to the previous year's revenue of $34,890. While Q4 2025 revenue showed a sequential increase to $4K, the overall annual performance indicates challenges in revenue generation and scaling the business.
Show more
1. Significant Q4 2025 Earnings Miss Led to Sharp Decline. Cardio Diagnostics reported a Q4 2025 Earnings Per Share (EPS) of -$0.80 on March 13, 2026, which fell short of analysts' expectations by -55.56%. This earnings disappointment directly impacted the stock, leading to a substantial -47.15% decrease in price within the 48-hour period following the report, dropping from $4.56 on March 12, 2026, to $2.41 on March 14, 2026.
2. Substantial Annual Revenue Contraction. The company experienced a significant decline in its full fiscal year 2025 revenue, which totaled $14,825. This represents a -57.51% decrease compared to the previous year's revenue of $34,890. While Q4 2025 revenue showed a sequential increase to $4K, the overall annual performance indicates challenges in revenue generation and scaling the business.
Show more
Stock Movement Drivers
Fundamental Drivers
The -31.8% change in CDIO stock from 11/30/2025 to 3/29/2026 was primarily driven by a -24.7% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.88 | 1.97 | -31.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -6.1% |
| P/S Multiple | 320.8 | 241.5 | -24.7% |
| Shares Outstanding (Mil) | 2 | 2 | -3.5% |
| Cumulative Contribution | -31.8% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CDIO | -31.8% | |
| Market (SPY) | -5.3% | 31.9% |
| Sector (XLV) | -8.7% | 11.9% |
Fundamental Drivers
The -48.4% change in CDIO stock from 8/31/2025 to 3/29/2026 was primarily driven by a -28.9% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.81 | 1.97 | -48.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -24.0% |
| P/S Multiple | 339.7 | 241.5 | -28.9% |
| Shares Outstanding (Mil) | 2 | 2 | -4.5% |
| Cumulative Contribution | -48.4% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CDIO | -48.4% | |
| Market (SPY) | 0.6% | 31.6% |
| Sector (XLV) | 5.2% | 11.6% |
Fundamental Drivers
The -85.4% change in CDIO stock from 2/28/2025 to 3/29/2026 was primarily driven by a -58.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.48 | 1.97 | -85.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | -58.5% |
| P/S Multiple | 307.7 | 241.5 | -21.5% |
| Shares Outstanding (Mil) | 1 | 2 | -55.3% |
| Cumulative Contribution | -85.4% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CDIO | -85.4% | |
| Market (SPY) | 9.8% | 4.5% |
| Sector (XLV) | -2.1% | -15.6% |
Fundamental Drivers
The -98.1% change in CDIO stock from 2/28/2023 to 3/29/2026 was primarily driven by a -82.6% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 103.50 | 1.97 | -98.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | � | 0 | 0.0% |
| P/S Multiple | � | 241.5 | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -82.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| CDIO | -98.1% | |
| Market (SPY) | 69.4% | 3.9% |
| Sector (XLV) | 18.4% | -11.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CDIO Return | - | -89% | 135% | -63% | -90% | -31% | -99% |
| Peers Return | 21% | -27% | 0% | -3% | 24% | 1% | 8% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| CDIO Win Rate | - | 75% | 42% | 33% | 42% | 33% | |
| Peers Win Rate | 65% | 38% | 45% | 50% | 55% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| CDIO Max Drawdown | - | -90% | -81% | -92% | -99% | -61% | |
| Peers Max Drawdown | -12% | -41% | -24% | -20% | -22% | -7% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ILMN, TMO, DGX, LH, EXAS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | CDIO | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.0% | -25.4% |
| % Gain to Breakeven | 5025.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
Compare to ILMN, TMO, DGX, LH, EXAS
In The Past
Cardio Diagnostics's stock fell -98.0% during the 2022 Inflation Shock from a high on 10/17/2022. A -98.0% loss requires a 5025.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Cardio Diagnostics (CDIO)
Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.
AI Analysis | Feedback
nullAI Analysis | Feedback
```html- Epi+Gen CHD™ test: An AI-driven, epigenetic-genetic test designed to assess an individual's risk for coronary heart disease (CHD).
- Precision Cardiovascular Medicine Platform: A comprehensive platform that integrates diagnostic tests and analytics to provide personalized cardiovascular risk assessment and management solutions.
AI Analysis | Feedback
Major Customers of Cardio Diagnostics (CDIO)
Cardio Diagnostics (symbol: CDIO) is a precision cardiovascular medicine company. Based on available public information, the company primarily sells its diagnostic tests to other companies and organizations rather than directly to individuals. Due to the company's relatively early stage of commercialization, specific publicly traded "major customers" (i.e., those accounting for 10% or more of revenue) are not publicly disclosed in financial filings. However, the company has indicated its sales strategy and identified customer categories. Cardio Diagnostics' customers and partners generally fall into the following categories:- Healthcare Providers and Health Systems: This includes physician groups, clinics, and hospitals that integrate Cardio Diagnostics' tests into their patient care pathways for early detection and prevention of cardiovascular disease.
- Self-Insured Employers: Companies that directly bear the cost of their employees' healthcare may offer Cardio Diagnostics' tests as part of their corporate wellness and preventive health programs.
- National Laboratories: These larger laboratories process tests for a wide network of healthcare providers and clients, acting as a channel for Cardio Diagnostics' tests to reach a broader patient population.
Specific customer companies or strategic partners mentioned in public communications include:
- Revere Health: Utah’s largest independent multispecialty physician group. (Note: Revere Health is a private company, not publicly traded).
- An unnamed major national laboratory: Cardio Diagnostics announced an agreement with a major national laboratory to expand access to its Anumana™ Heart Health Test, though the name of this laboratory has not been disclosed.
AI Analysis | Feedback
nullAI Analysis | Feedback
Meeshanthini Dogan, PhD Chief Executive Officer
Dr. Meesha Dogan is the Co-Founder and Chief Executive Officer of Cardio Diagnostics Holdings, Inc., serving as CEO and a director since the company's inception in 2017. She is a co-inventor of the company's proprietary Integrated Genetic-Epigenetic Engine™, a core technology for cardiovascular solutions. Her background includes extensive work in AI/ML applications within biomedical engineering. Dr. Dogan holds a PhD in Biomedical Engineering and BSE/MS degrees in Chemical Engineering from the University of Iowa. She has been recognized with several awards, including Nature/Merck "One To Watch" (2020), Biotech Breakthrough "Clinical Diagnostics Solution of the Year" (2021), and Fast Company "Next Big Things in Tech" (2022).
Elisa Luqman Chief Financial Officer
Elisa Luqman has served as the Chief Financial Officer of Cardio Diagnostics Holdings, Inc. on a part-time basis since March 2021. Ms. Luqman was a co-founder of bigVault Storage Technologies, a cloud-based file hosting company that was acquired by Digi-Data Corporation in February 2006. Following the acquisition, she served as Chief Operating Officer of Digi-Data's Vault Services Division and later as General Counsel for the corporation. She also served as Chief Financial Officer and General Counsel of Clinigence Holdings, Inc. (CLNH) since October 2019, overseeing SEC and FINRA filings through its reverse merger with Clinigence Holdings, Inc. Since April 2022, she has also been Chief Legal Officer (SEC) for Nutex Health, Inc.
Timur Dogan, PhD Chief Technology Officer
Dr. Timur (Tim) Dogan has served as the Chief Technology Officer of Cardio Diagnostics Holdings, Inc. since May 2022. He joined the company in August 2019 as its first employee, initially as a Senior Data Scientist, and was instrumental in developing and advancing the Integrated Genetic-Epigenetic Engine™. Dr. Dogan is also a co-inventor of several patent-pending technologies in cardiovascular disease and diabetes. He holds joint B.S.E./M.S. and Ph.D. degrees in Mechanical Engineering from the University of Iowa, where his research focused on complex fluid flows and machine learning models on high-performance computing systems.
Robert Philibert, MD, PhD Chief Medical Officer
Dr. Robert Philibert is a Co-Founder and Chief Medical Officer of Cardio Diagnostics Holdings, Inc. He is a co-inventor of the Integrated Genetic-Epigenetic Engine™ that forms the core of Cardio Diagnostics' cardiovascular solutions. In 2009, Dr. Philibert founded Behavioral Diagnostics, LLC, a company providing epigenetic testing services that successfully introduced two epigenetic tests, Smoke Signature© and Alcohol Signature™, to the commercial market. He is widely published with over 200 peer-reviewed manuscripts and holds numerous NIH grant awards and national and international patents for his pioneering work in epigenetics, including the discovery of epigenetic signatures for cigarette and alcohol consumption. He holds joint appointments in Neuroscience, Molecular Medicine, and Biomedical Engineering.
AI Analysis | Feedback
Here are the key risks to Cardio Diagnostics (CDIO):- Limited Operating History, Financial Viability, and Dependence on Capital Raising: Cardio Diagnostics has a limited operating history and an unproven business model, with no assurance of profitability. The company has reported minimal sales and significant net losses, indicating a challenging financial environment. Furthermore, Cardio Diagnostics has engaged in ongoing capital raises through "at-the-market" sales agreements, which can lead to dilution for existing shareholders and highlights a continuous reliance on external funding to support operations and growth.
- Regulatory Risks for Laboratory-Developed Tests (LDTs): The company faces significant regulatory risks, particularly concerning potential changes in FDA rules for laboratory-developed tests. As Cardio Diagnostics specializes in AI-driven multi-omics diagnostic tests, any new or altered regulatory scrutiny could materially affect its commercialization efforts and ability to bring products to market.
- Market Adoption, Reimbursement, and Competition: The success of Cardio Diagnostics' innovative AI-driven diagnostic tests is contingent upon widespread market adoption and securing favorable reimbursement from government and commercial payors. The company's market opportunity estimates may also be inaccurate. Additionally, the biotechnology and diagnostic markets are competitive, requiring the company to successfully expand its product portfolio, gain market acceptance, and navigate a competitive landscape to achieve sustained growth and profitability.
AI Analysis | Feedback
nullAI Analysis | Feedback
Cardio Diagnostics (NASDAQ: CDIO) specializes in precision cardiovascular medicine, utilizing epigenetics and artificial intelligence to offer advanced blood tests for the prevention and early detection of heart disease.
The company's primary products and their addressable markets in the U.S. are as follows:
- Epi+Gen CHD: This AI-powered blood test estimates a patient's three-year risk of coronary heart disease. The estimated total addressable market for Epi+Gen CHD in the U.S. is approximately $125 billion, with about 146 million eligible Americans.
- PrecisionCHD: This AI-powered blood test serves as a diagnostic aid for the early detection of coronary heart disease. The estimated total addressable market for PrecisionCHD in the U.S. is approximately $51 billion, with about 60 million eligible Americans.
Combined, the total addressable market across both Epi+Gen CHD and PrecisionCHD in the U.S. is over $176 billion.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Cardio Diagnostics (CDIO) over the next 2-3 years:
- Expansion of Reimbursement and Payer Coverage: Cardio Diagnostics anticipates revenue growth by leveraging CPT PLA codes and actively expanding reimbursement agreements with both government and commercial payers. The company is prioritizing health economics evidence generation to support the adoption of its diagnostic tests, Epi+Gen CHD™ and PrecisionCHD™.
- New Product Development and Pipeline Expansion: The company's strategic initiatives include the development of additional AI-driven multi-omics diagnostic products for other significant cardiovascular diseases such as stroke, heart failure, and diabetes. This expansion of its product pipeline is expected to create new revenue streams.
- Market Expansion (Geographical and Channel): Cardio Diagnostics is pursuing significant market expansion, exemplified by its first international entry into India through strategic partnerships with Aimil Ltd. and Dr. Lal PathLabs, with a commercial rollout expected in 2026. Domestically, the company is also focused on increasing adoption across health systems, self-insured employers, and various provider organizations.
- Increased Adoption of Existing AI-driven Diagnostic Tests: Growth is expected from the wider adoption of its current cutting-edge blood tests, Epi+Gen CHD™ for CHD risk assessment and PrecisionCHD™ for earlier detection. The company is expanding its evidence portfolio and engaging in partnerships to drive this adoption among clinicians, health systems, payers, and self-insured employers.
AI Analysis | Feedback
Share Issuance
- Shareholders approved a proposal on October 15, 2025, to authorize future issuances of common stock and/or convertible or exercisable securities representing 20% or more of outstanding common stock in non-public transactions.
- The number of shares outstanding increased by 123.64% in one year to 1.83 million shares.
- Cardio Diagnostics raised over $15 million in capital through sales of common stock as of November 12, 2025, with $3.5 million from sales of common stock and warrants in the nine months ended September 30, 2025.
Inbound Investments
- As of November 12, 2025, the company had raised more than $15 million in capital through sales of common stock.
- Cash from sales of common stock and warrants amounted to $3.5 million for the nine months ended September 30, 2025.
- The company reported cash of $6,355,218 as of September 30, 2025, and relies on At-The-Market (ATM) funding to support its cash position.
Capital Expenditures
- Capital expenditures were reported as $163K in Q3 2025.
- In the last 12 months, capital expenditures were -$190,955.
- The primary focus of capital expenditures is on the development of the company's AI-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease, including $29,264 spent on office and computer equipment for the nine months ended September 30, 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Is Cardio Diagnostics Stock Built to Withstand More Downside? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to CDIO.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 195.51 |
| Mkt Cap | 21.1 |
| Rev LTM | 11,035 |
| Op Inc LTM | 1,516 |
| FCF LTM | 1,206 |
| FCF 3Y Avg | 1,044 |
| CFO LTM | 1,640 |
| CFO 3Y Avg | 1,497 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.9% |
| Rev Chg 3Y Avg | 3.5% |
| Rev Chg Q | 5.6% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Mgn LTM | 14.1% |
| Op Mgn 3Y Avg | 9.6% |
| QoQ Delta Op Mgn LTM | -0.0% |
| CFO/Rev LTM | 17.1% |
| CFO/Rev 3Y Avg | 14.8% |
| FCF/Rev LTM | 12.3% |
| FCF/Rev 3Y Avg | 10.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 21.1 |
| P/S | 4.0 |
| P/EBIT | 15.1 |
| P/E | 21.3 |
| P/CFO | 13.3 |
| Total Yield | 4.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.1% |
| 3M Rtn | -12.8% |
| 6M Rtn | 2.1% |
| 12M Rtn | 16.1% |
| 3Y Rtn | -15.1% |
| 1M Excs Rtn | -0.1% |
| 3M Excs Rtn | -4.9% |
| 6M Excs Rtn | 6.8% |
| 12M Excs Rtn | 2.9% |
| 3Y Excs Rtn | -75.6% |
Price Behavior
Price Behavior
| Market Price | $1.97 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/14/2022 | |
| Distance from 52W High | -87.4% | |
| 50 Days | 200 Days | |
| DMA Price | $2.69 | $3.45 |
| DMA Trend | down | up |
| Distance from DMA | -26.8% | -43.1% |
| 3M | 1YR | |
| Volatility | 261.2% | 3,333.6% |
| Downside Capture | 4.08 | 5.72 |
| Upside Capture | 607.91 | 507.48 |
| Correlation (SPY) | 30.5% | 4.5% |
CDIO Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 14.70 | 9.28 | 8.65 | 5.34 | 7.39 | 4.91 |
| Up Beta | 14.88 | 16.95 | 15.05 | 7.98 | 0.15 | 2.20 |
| Down Beta | 3.00 | 1.02 | 1.73 | 3.24 | 1.59 | 2.03 |
| Up Capture | 5910% | 2669% | 3013% | 1490% | 13476% | 5682% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 10 | 17 | 26 | 54 | 113 | 313 |
| Down Capture | 283% | 461% | 445% | 293% | 177% | 113% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 11 | 24 | 34 | 68 | 135 | 423 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CDIO | |
|---|---|---|---|---|
| CDIO | -85.2% | 3,320.4% | 0.95 | - |
| Sector ETF (XLV) | 0.3% | 17.6% | -0.13 | -16.0% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 4.4% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 1.6% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 9.1% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | -7.4% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 4.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CDIO | |
|---|---|---|---|---|
| CDIO | -58.0% | 1,738.4% | 0.52 | - |
| Sector ETF (XLV) | 6.0% | 14.5% | 0.23 | -9.9% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 3.3% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 1.2% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 5.1% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | -3.0% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 1.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CDIO | |
|---|---|---|---|---|
| CDIO | -35.2% | 1,738.4% | 0.52 | - |
| Sector ETF (XLV) | 9.7% | 16.5% | 0.48 | -9.9% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 3.3% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 1.2% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 5.1% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | -3.0% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 1.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 03/13/2026 | 10-K |
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/15/2025 | 10-Q |
| 12/31/2024 | 03/20/2025 | 10-K |
| 09/30/2024 | 11/13/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 04/01/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/14/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 06/30/2022 | 10/07/2022 | 424B3 |
| 03/31/2022 | 05/31/2022 | S-4 |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.